Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Research & Development (2018 - 2025)

UroGen Pharma's Research & Development history spans 8 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, Research & Development fell 3.89% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $67.1 million, up 17.43%, while the annual FY2025 figure was $67.1 million, 17.43% up from the prior year.
  • Research & Development reached $14.3 million in Q4 2025 per URGN's latest filing, up from $14.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $19.9 million in Q1 2025 to a low of $10.2 million in Q3 2023.
  • Average Research & Development over 5 years is $13.5 million, with a median of $12.9 million recorded in 2021.
  • The largest YoY upside for Research & Development was 49.57% in 2021 against a maximum downside of 36.62% in 2021.
  • A 5-year view of Research & Development shows it stood at $13.1 million in 2021, then increased by 10.66% to $14.5 million in 2022, then decreased by 21.93% to $11.3 million in 2023, then soared by 31.78% to $14.9 million in 2024, then dropped by 3.89% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Research & Development are $14.3 million (Q4 2025), $14.0 million (Q3 2025), and $18.9 million (Q2 2025).